Next Article in Journal
DOCK1 Regulates Growth and Motility through the RRP1B-Claudin-1 Pathway in Claudin-Low Breast Cancer Cells
Previous Article in Journal
Verteporfin-Loaded Lipid Nanoparticles Improve Ovarian Cancer Photodynamic Therapy In Vitro and In Vivo
Previous Article in Special Issue
Toxicity Profiles of Fractionated Radiotherapy, Contemporary Stereotactic Radiosurgery, and Transsphenoidal Surgery in Nonfunctioning Pituitary Macroadenomas
Open AccessArticle

The New Genetic Landscape of Cushing’s Disease: Deubiquitinases in the Spotlight

1
Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, D-97080 Würzburg, Germany
2
Comprehensive Cancer Center Mainfranken, University of Würzburg, D-97080 Würzburg, Germany
3
Chair of Medical Informatics, Friedrich-Alexander University of Erlangen-Nürnberg, D-91058 Erlangen, Germany
4
Department of Bioinformatics, Biocenter, University of Würzburg, D-97074 Würzburg, Germany
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(11), 1761; https://doi.org/10.3390/cancers11111761
Received: 4 October 2019 / Revised: 28 October 2019 / Accepted: 4 November 2019 / Published: 8 November 2019
Cushing’s disease (CD) is a rare condition caused by adrenocorticotropic hormone (ACTH)-producing adenomas of the pituitary, which lead to hypercortisolism that is associated with high morbidity and mortality. Treatment options in case of persistent or recurrent disease are limited, but new insights into the pathogenesis of CD are raising hope for new therapeutic avenues. Here, we have performed a meta-analysis of the available sequencing data in CD to create a comprehensive picture of CD’s genetics. Our analyses clearly indicate that somatic mutations in the deubiquitinases are the key drivers in CD, namely USP8 (36.5%) and USP48 (13.3%). While in USP48 only Met415 is affected by mutations, in USP8 there are 26 different mutations described. However, these different mutations are clustering in the same hotspot region (affecting in 94.5% of cases Ser718 and Pro720). In contrast, pathogenic variants classically associated with tumorigenesis in genes like TP53 and BRAF are also present in CD but with low incidence (12.5% and 7%). Importantly, several of these mutations might have therapeutic potential as there are drugs already investigated in preclinical and clinical setting for other diseases. Furthermore, network and pathway analyses of all somatic mutations in CD suggest a rather unified picture hinting towards converging oncogenic pathways. View Full-Text
Keywords: Cushing’s disease; pathogenesis; somatic mutations; deubiquitinases Cushing’s disease; pathogenesis; somatic mutations; deubiquitinases
Show Figures

Figure 1

MDPI and ACS Style

Sbiera, S.; Kunz, M.; Weigand, I.; Deutschbein, T.; Dandekar, T.; Fassnacht, M. The New Genetic Landscape of Cushing’s Disease: Deubiquitinases in the Spotlight. Cancers 2019, 11, 1761.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop